[Scintigraphic detection of malignancies with radioactively labelled tumor antibodies. Clinical results based on immunohistochemical research].
69 patients with different tumors (colorectal, melanoma, testicle, ovary, bladder, carcinoid, lungs) were investigated by radioimmunoscintigraphy. The corresponding antibodies or their F(ab')2 fragments against CEA (n = 30), melanoma antigen (n = 25), TPA (n = 6), beta-HCG (n = 5), HMFG-2 (n = 2) and CEA/CA 19-9 (n = 1) were selected on the basis of immunohistochemical investigations of the primary tumors. The precision was 62%, and the number of false-negative findings was 32%. Additional clinical information (detection or exclusion of a suspected recurrence) could be obtained in 22 patients. From these results, it can be concluded that the corresponding tumor antibodies should be selected on the basis of immunohistochemical investigations of the primary tumor before performing radioimmunoscintigraphy to screen for recurrences or metastases.
D000911:Antibodies, Monoclonal; D000912:Antibodies, Neoplasm / Q000032:analysis*; D000951:Antigens, Neoplasm / Q000032:analysis; D000954:Antigens, Surface / Q000032:analysis; D015295:Antigens, Tumor-Associated, Carbohydrate; D002272:Carcinoembryonic Antigen / Q000032:analysis; D006063:Chorionic Gonadotropin / Q000276:immunology; D018997:Chorionic Gonadotropin, beta Subunit, Human; D005260:Female; D006651:Histocytochemistry; D006801:Humans; D008297:Male; D008545:Melanoma / Q000276:immunology; D058950:Melanoma-Specific Antigens; D008565:Membrane Proteins / Q000032:analysis; D018396:Mucin-1; D009363:Neoplasm Proteins / Q000032:analysis; D009369:Neoplasms / Q000000981:diagnostic imaging* / Q000276:immunology / Q000378:metabolism; D010446:Peptide Fragments / Q000276:immunology; D010455:Peptides / Q000032:analysis; D011877:Radionuclide Imaging; D019396:Tissue Polypeptide Antigen
D000911:Antibodies, Monoclonal; D000912:Antibodies, Neoplasm; D000951:Antigens, Neoplasm; D000954:Antigens, Surface; D015295:Antigens, Tumor-Associated, Carbohydrate; D002272:Carcinoembryonic Antigen; D006063:Chorionic Gonadotropin; D018997:Chorionic Gonadotropin, beta Subunit, Human; D058950:Melanoma-Specific Antigens; D008565:Membrane Proteins; D018396:Mucin-1; D009363:Neoplasm Proteins; D010446:Peptide Fragments; D010455:Peptides; D019396:Tissue Polypeptide Antigen
Szintigraphischer Malignomnachweis mit radioaktiv markierten Tumorantikörpern. Klinische Ergebnisse auf der Basis immunhistochemischer Untersuchungen.